Phase III trial of modified-release dexamfetamine [HLD 100] in attention-deficit hyperactivity disorder

Trial Profile

Phase III trial of modified-release dexamfetamine [HLD 100] in attention-deficit hyperactivity disorder

Planning
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2013

At a glance

  • Drugs Dexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2013 New trial record
    • 25 Jun 2013 This trial is anticipated to start in the first quarter of 2014, and its trial design will be dependent on the outcomes of the phase II trial, according to a Highland Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top